prehensive data on sporadic renal cell tumors are missing. We therefore tested a large cohort of sporadic renal tumors for MITF p.E318K mutation status. Methods: Genomic DNA was extracted from 426 formalin-fixed, paraffin-embedded sporadic renal tumors that had been graded according to the 2004 WHO classification of renal tumors and staged according to the 2002 TNM classification. The tumor cohort was enriched with papillary and chromophobe RCC, and also contained benign oncocytomas. DNA was tested for MITF p.E318K by pyrosequencing. Results: Of 403 analyzable tumors, 402 renal tumors were wild-type ones, and only 1 case showed the MITF p.E318K mutation. This tumor was a clearcell RCC (pT3b N0 M0 G3 according to the TNM classification 2002). The affected patient was male, 61 years old, and had no known coexisting malignancies. Conclusion: The MITF p.E318K mutation does not appear to play a major role in sporadic RCC carcinogenesis, but is possibly restricted to a rare subpopulation of inherited RCC.
Introduction
Cellular functions and intracellular communication are controlled and regulated both at the DNA and posttranslational levels. Posttranslational modifications (e.g. phosphorylation, ubiquitination, and acetylation) of proteins are essential for triggering signal cascades and for maintaining fundamental developmental processes. Dysregulation of posttranslational modification might lead to dramatic malfunction of the cell, and is known from most malignancies. However, as recently demonstrated, a deregulated posttranslational modification network may act as a therapeutic target (e.g. in pancreatic cancer), and is a major focus of ongoing studies in prostate cancer [1, 2] .
Reversible covalent conjugation of SUMO (small ubiquitin-related modifier) is a posttranslational modification that can modulate the function (e.g. activity, cellular localization, and stability) of a large spectrum of proteins [3] . SUMOylation frequency of a target protein is increased by the presence of the consensus motif ΨKXE, but proteins without this motif might also be prone to this modification [4] . Of important functional relevance is a connection between the SUMOylation and ubiquitination networks, as SUMOylation can lead to ubiquitindependent degradation by the proteasome [5] .
The MITF (microphthalmia-associated transcription factor) gene encodes for a basic-helix-loop-helix leucine zipper transcription factor and is part of the Myc supergene family. The MITF gene contains two SUMOylation sites that can regulate SUMOylation and transcriptional activity of the MITF protein [6] .
Recently, a germline missense mutation (p.E318K) in the MITF gene was described, and a predisposition to familial and sporadic melanoma in carriers of this specific change was documented. The affected codon is located within a SUMOylation consensus motif, and the mutation interferes with MITF SUMOylation. In vitro studies revealed both enhanced binding of mutated MITF to the promoter of the hypoxia-inducible factor (HIF1-α) gene, which is a target gene of the MITF transcription factor, and increased activity of the HIF1-α promoter caused by this binding [7, 8] . Increased expression of HIF1-α is correlated with the development of clear-cell renal cell carcinomas (RCC), and overexpression of HIF1-α has been found in most clear-cell RCC cases analyzed to date [9] . Most interesting, a significantly increased frequency of RCC compared to normal controls was detected in melanoma patients with the p.E318K germline mutation in MITF [7, 10] . These findings suggest MITF as a possible connection point between melanoma and RCC. In addition, mutation analysis of a small cohort of sporadic RCC cases showed a MITF p.E318K mutation frequency of 1.5% [7] . Currently, the role of the MITF mutation in RCC development remains unclear, as comprehensive mutation data from sporadic RCC cases are missing. Therefore, the aim of our study was to screen a large cohort of Caucasian sporadic renal tumor cases for the MITF p.E318K mutation.
Materials and Methods

Patients and Tissue Samples
Overall, 426 formalin-fixed, paraffin-embedded archival sporadic renal tumors were used for the study. The cases were classified according to the 2004 WHO classification of renal tumors and staged according to the 2002 TNM classification [11, 12] . Characteristics of the study cohort are shown in table 1 . Prior institutional review board approval (University Hospital Erlangen, Germany) was obtained for the study. Tissue Microdissection and DNA Isolation DNA was extracted from renal tumor samples from serial sections after manual microdissection as described previously [13] . In brief, 5-μm-thick serial sections of the tumor tissue were dewaxed and stained with 0.1% methylene blue for 15 s. Using an inverted microscope, the tumor tissue (identified through matching with a marked hematoxylin and eosin-stained section reviewed by an experienced surgical pathologist) was scraped off with a sterile needle to obtain a purity of the cells of at least 85%. Isolation of genomic DNA of the microdissected tumor tissue was performed using the High Pure PCR Template Preparation Kit (Roche, Mannheim, Germany) according to the manufacturer's instructions.
Sequence Analysis of Codon 318 of MITF
For mutation analysis, the hot spot region of the MITF gene containing codon 318 was amplified using the multiplex PCR-kit according to manufacturer's instructions (Qiagen, Hilden, Germany) and the following primers: forward: 5 ′ -TTATTCCATC-CACGGGTCTC-3 ′ , and reverse: 5 ′ -biotin GAGGTCTTGGCTG-CAGTTCT-3 ′ . The cycling conditions were as follows: a single cycle of denaturation at 94 ° C for 5 min, 45 cycles at 94 ° C for 1 min, 58.3 ° C for 1 min, and 72 ° C for 1 min, and a final 10-min extension at 72 ° C. For pyrosequencing (PyroMark Q24; Qiagen) single-stranded DNA was prepared from 25 ml of biotinylated PCR product with streptavidin-coated sepharose and 0.5 m M of the sequencing primer 5 ′ -AATCGGATCATCAAGC-3 ′ using the PSQ Vacuum Prep Tool (Qiagen). Pyrosequencing assay setup was selected in 'Sequence to Analyze' with the sequence AAG/A AAC CCG TT. The following dispensation order was used: GAA GAC GT.
Results
Sequencing data were available from 403/426 (94.6%) cases. In 23 cases, no PCR products were obtained due to strong fragmentation of the DNA after formalin fixation. Of the 403 analyzable cases, 402 (99.8%) showed wildtype MITF p.E318. Only 1 (0.2%) case showed the MITF p.E318K mutation ( fig. 1 ). This case was a clear-cell RCC (pT3b N0 M0 G3 according to the TNM classification 2002). The affected patient was male, 61 years old, and had no known coexisting malignancies.
Discussion
In this study we analyzed the p.E318K mutation of MITF in a large cohort of sporadic renal cell tumors. Only one of the cases investigated showed the mutation known as a germline alteration from patients with familial melanoma and/or RCC. The resulting allele frequency of the mutation in our cohort was 0.12%. The low frequency detected might hint to technical problems or contaminated material, but positive and negative controls showed the expected results. Moreover, this mutation frequency was comparable to those of the general populations of France (frequency = 0.3%), Australia (frequency = 0.72%), Poland (0.09%), and the UK (frequency = 0.85%) [8, 14, 15] . Furthermore, Guo et al. [16] performed exome sequencing on 10 clear-cell RCC and screened >1,000 genes (including MITF) in an additional 88 clear-cell RCC cases, but could not detect an MITF mutation. Furthermore, the TCGA Research Network published an extensive molecular profiling of 417 clearcell RCC samples. Overall, MITF alterations were reported in 2.6% of the cases with 9/11 mutated tumors showing deep deletions and only 2/11 mutated tumors displaying point mutations (p.T110M, p.G165D). The p.E318K mutation could not be detected at all [17] . Through cBioPortal [18, 19] , provisional sequencing data from an additional 161 papillary RCC cases analyzed by the TCGA Research Network are available. In this cohort, 3/161 (2.6%) cases showed truncating (p. K118 * , p.K198fs) or missense (p.A205V) mutations within the MITF gene. Again, the p.E318K mutation allele was not found. Thus, combining all available data, the overall MITF mutation frequency is approximately 1.4% (15/1,079 cases with mutation).
Altogether, these data support our results on MITF p.E318K frequency in sporadic RCC and therefore argue for their validity. In conclusion, the MITF p.E318K mutation only plays a minor role in the development of sporadic RCC.
Despite the rarity of MITF mutations, they might trigger RCC development in specific cases, as mutated MITF displays enhanced binding to the HIF1-α promoter and has been shown to increase HIF1-α promoter activity. Moreover, MITF also acts as a transcription factor and is able to directly control MET transcription [20] . Activating mutations in the MET proto-oncogene are especially frequent in papillary type 1 RCC (about 15%) [21] . These mutations lead to activation of several pathways resulting in, for example, tumor cell proliferation, invasion, and angiogenesis. Mutations in MITF interrupting its controlled degradation might constantly increase MET transcription and result in similar effects as mutational MET activation. It is conceivable that this effect, in combination with additional harmful events, makes a cell prone to malignant transformation. This is supported by the recent description of an actin gamma 1 (ACTG1)-MITF fusion in a case of papillary RCC [22] . In vitro studies of this fusion protein revealed an induction of, for example, HIF1-α and MET transcription in HEK293T cells, and an increased colony-forming ability in NIH3T3 cells. These data gave the first evidence for a similar tumorigenic potential of MITF fusion proteins as is attributed to TFE3 fusions.
In summary, the MITF p.E318K mutation does not seem to play a major role in sporadic RCC development in Caucasians, but is possibly restricted to a rare subpopulation of inherited RCC. Nonetheless, in general, MITF alterations might contribute to the development of sporadic RCC as they affect targets already known to be involved in RCC pathobiology.
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